Head-to-head · WeighScore
Ageless vs Ilant Health
The verdict
Ageless takes it — 84.8/100 to 56.8/100.
Ageless grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the broadest compounded storefronts on the board — GLP-1, NAD+, sermorelin, TRT and more under one roof, in both injectable and oral routes, on low headline pricing (semaglutide $119/mo, tirzepatide $169/mo) — offset by a compounded-only catalog and an undisclosed state list.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ageless | Ilant Health |
|---|---|---|
| WeighScore | 84.8/100 | 56.8/100 |
| Grade | B | C |
| Scorecard rank | #10 | #407 |
| Semaglutide | $119/mo | Not disclosed |
| Tirzepatide | $169/mo | Not disclosed |
| Coverage | Varies by state | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #10 · B
Strengths
- Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
- Low headline GLP-1 pricing — semaglutide $119/mo, tirzepatide $169/mo — no insurance, with Klarna/Affirm financing
- Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures
- Oral routes available (drops and troches), not injection-only
Where it loses points
- Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
- Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
- No published state-availability list and no named legal entity or medical group
- Thin public track record, and advertised prices are floors set after clinical review
Graded #407 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.